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Abstract
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Francisella tularensis, the etiological agent of tularemia, is one of the most infectious bacterial
pathogens known. No vaccine is currently approved for public use. Previously, we identified epitopes
recognized specifically by T cells obtained from individuals following infection with F. tularensis.
Here, we report that a subunit vaccine constructed based upon these epitopes elicited protective
immunity in “humanized” HLA class II (DRB1*0401) transgenic mice. Vaccinated mice challenged
intratracheally with a lethal dose of F. tularensis (Live Vaccine Strain) exhibited a rapid increase in
pro-inflammatory cytokine production and diminished number of organisms in the lungs, and a
concurrent increased rate of survival. These results demonstrate the efficacy of an epitope-based
tularemia vaccine and suggest that such an approach might be widely applicable to the development
of vaccines specific for intracellular bacterial pathogens.
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1. Introduction
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Francisella tularensis, the etiological agent of tularemia, is a small, gram-negative, facultative
intracellular coccobacillus [1]. Tularemia is a zoonotic disease; small mammals including mice,
squirrels, rats and rabbits are natural reservoirs. Human infections usually occur through
incidental environmental exposure, e.g., contact or ingestion of contaminated food, water or
soil, bites by infected arthropods, inhalation of infective aerosols. Lymph nodes, lungs, spleen,
liver and kidneys are major target organs [2]. F. tularensis is divided into two major subspecies:
tularensis (type A), which is highly virulent and the most common form found in North
America; and holarctica (type B), a less virulent form that causes most human illnesses in
Europe and Asia [3]. Clinical presentations include glandular, ulceroglandular, intestinal and
pneumonic forms dependent upon route of infection. The organism is difficult to identify
microscopically; unfamiliarity with its presentation can delay proper diagnosis and treatment.
In the absence of prompt antibiotic therapy, inhalation of as few as 10 organisms can cause
severe pneumonia and 80% mortality [4,5]. As such, aerosolized F. tularensis represents a
potentially dangerous biological weapon, classified by CDC as a category A select agent [6].
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Cell-mediated immunity is the dominant factor in host resistance to tularemia; both CD4+ and
CD8+ T cells are key elements in the efficient resolution of primary and secondary infections
[1,7]. Mice inoculated intraperitoneally (i.p.) with immune sera exhibit FcγR-dependent
protection from lethal intranasal (i.n.) challenge suggesting that B cells and antibody
production might play an additional role [8,9]. Both interferon gamma (IFN-γ) and tumor
necrosis alpha (TNF-α) are also critical factors in primary host defenses to systemic infections
in mice [10]. It is speculated that IFN-γ and TNF-α synergize to promote nitric oxide
production, and to regulate iron homeostasis and pH thus limiting F. tularensis survival within
macrophages, the primary site of intracellular replication in vivo [11,12].
Until recently, immunization with an attenuated Live Vaccine Strain (LVS) of F. tularensis
subsp. holarctica was used to protect laboratory personnel working with F. tularensis.
Vaccination by scarification, however, provides human volunteers only incomplete protection
against challenge with aerosolized F. tularensis type A [13]. Furthermore, several safety issues
exist. For one, the molecular basis for the attenuation of F. tularensis LVS has never been
established. Moreover, culture conditions contribute to variations in the pathogenicity of the
attenuated strain rendering F. tularensis LVS an unreliable vaccine and potentially hazardous
particularly to immunocompromised individuals [14,15]. Despite considerable need and years
of research, no tularemia vaccine is currently approved for public use.
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Efforts to develop a safe, effective vaccine against F. tularensis have focused on three different
strategies: inactivated whole cell, attenuated and subunit vaccines. Heat- or chemicallyinactivated whole-cell preparations have generally failed to elicit sufficient protective
immunity in either humans or animal models though vaccination with paraformaldehyde-fixed
F. tularensis LVS administered in conjunction with IL-12 or targeted to Fc receptors via antiF. tularensis LPS mAb has shown promise in recent studies [16,17]. Live attenuated organisms
are considered a logical alternative approach to vaccine development given the ability of F.
tularensis LVS to reduce the incidence of laboratory-acquired infections [18]. Recent efforts
have targeted virulence and metabolic genes to create weakened mutants capable of eliciting
protective immunity, yet limited in their ability to survive, replicate, and cause disease [19,
20]. Nonetheless, even the attenuated vaccines that meet these criteria represent considerable
risk to immunocompromised individuals. Moreover, the failure of current live-attenuated F.
tularensis vaccine developers to resolve issues regarding the basis of attenuation and
mechanisms of action provides significant reason for concern about safety on the part of
regulatory authorities, and creates a nearly insurmountable obstacle to licensure, marketing,
and possible stockpile acquisition.
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Subunit vaccines, consisting of a single antigen or set of antigens, constitute a third approach
to immunizing against F. tularensis. To date, only the O-antigenic component of the LPS
molecule derived from F. tularensis, was found to elicit protective immunity to systemic
infections by Type B, but not Type A, strains of F. tularensis [21]. Undoubtedly, this is due
in part to the failure of LPS to induce a T cell response required for protection. Additionally,
the results suggest that a subunit vaccine must be composed of more than a single antigen in
order to elicit protective immunity. Computer analysis of the microbial genome coupled with
algorithms that predict T cell epitopes associated with a multiplicity of immunogenic proteins
offers a means of generating an effective, low cost subunit vaccine capable of provoking a
broad T cell response to a large number of antigens. Using this approach, we previously
identified a number of epitopes that were subsequently recognized specifically by T cells
obtained from individuals following infection with F. tularensis [22]. Here, we report that a
subunit vaccine constructed based upon these clinically relevant epitopes elicited protective
immunity in “humanized” HLA class II (DRB1*0401) transgenic mice.
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2. Materials and Methods
2.1. Francisella tularensis live vaccine strain (LVS)
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F. tularensis LVS was obtained from the Centers for Disease Control and Prevention (Division
of Vector-Borne Infectious diseases, Fort Collins, CO). The bacteria were grown in Mueller
Hinton broth (Difco, Detroit, MI) supplemented with 0.1% glucose, 0.025% ferric
pyrophosphate (Sigma Chemical, St. Louis, MO), 2.0% Isovitalex (Becton Dickinson,
Cockeysville, MD) and 2.5% FBS, harvested at mid-log phase of growth, centrifuged,
resuspended in fresh broth mixed 1:1 with 2.6% gelatin, and stored frozen at −80°C until use.
The numbers of bacteria in the lungs, spleens and livers of infected mice were estimated from
the colonies that grew on supplemented Mueller-Hinton agar plates inoculated with an aliquot
of organ homogenate and cultured for 4 days at 37°C in a humidified environment composed
of 5% CO2 in air. In preliminary experiments, 1 LD50 was found equivalent to 1,280 CFUs F.
tularensis LVS inoculated intratracheally as described below.
2.2. Animals
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Specific pathogen-free HLA-DRB1 transgenic mice (DRB1*0401 on a B10.M background)
were obtained from Dr. Dennis Zaller, Merck Research Laboratories, Rahway, NJ [23]; a
colony was bred and maintained at Taconic Farms, Inc., Germantown, NY. HLA-DRB1 mice
express recombinant MHC class II molecules in which the α1 and β1 domains of mouse I-E
were replaced by the corresponding domains of human DRB1*0401 (DR4Dw4) molecules; as
such, mouse MHC class II I-E are not expressed. Mice imported into the Rhode Island Hospital
central animal facility were treated in accordance with NIH publications entitled "Principles
for Use of Animals" and "Guide for the Care and Use of Laboratory Animals." The mice were
housed in well-ventilated rooms maintained at 22°C and an alternating 12-hour light and dark
cycle; food and water were provided ad libitum. All experiments were conducted using female
animals between 6 and 8 weeks of age at the time of initiation. The mice were infected
intratracheally in accordance with methods previously described [24]. Briefly, a 50µl aliquot
of bacteria suspended in saline was delivered to the back of the oropharyngeal cavity of mice
deeply anesthetized with isoflurane, temporarily occluding airflow; the bacteria were inhaled
as the animals revived.
2.3. Epitope-based DNA vaccine construct
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Prediction and validation of the HLA class II-restricted epitopes incorporated into the vaccine
construct reported here were previously described in detail [22]. Briefly, computational tools
were used to scan the fully annotated F. tularensis subsp. tularensis genome (Schu4 strain)
[25] and to identify gene sequences most likely to encode secreted proteins (Genome Scan 1);
147 putative proteins were identified. An additional 53 proteins were gleaned from the literature
(Genome Scan 2). The EpiMatrix System was then used to screen the combined set of 200
selected proteins for the presence of class II-restricted T cell epitope clusters. Twenty-seven
promiscuous epitopes capable of binding a set of 8 archetype/supertype class II matrices
including both HLA DRB1*0101 and HLA DRB1*0401 were synthesized as peptides.
Twenty-four synthesized peptides elicited IFN-γ production in ELISpot assays using PBMCs
derived from individuals previously infected with F. tularensis, thus validating their relevance.
Of these, 14 peptides (shown in Table 1) were bound by HLA DRB1*0101 in an in vitro
competitive binding assay. These fourteen epitopes were selected for inclusion in a candidate
vaccine construct; 13 epitopes were immunogenic in peptide immunizations of DRB1*0401
transgenic mice (data not shown). One epitope (GS1_Secr_II_3001) not meeting any of the
criteria was included as an internal negative control. The candidate epitopes were aligned in a
string-of-beads conformation shown in Figure 1A.
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Of the sequences incorporated into the synthetic gene, 6 were 100% conserved between F.
tularensis LVS and the virulent Schu4 strain, 4 were partially conserved, and 4 were only found
in F. tularensis Schu4 (Figure 1B). A “breaker” sequence (GlyProGlyPro) was inserted
between each epitope pair in order to minimize the introduction of MHC binding “neoepitopes” at the junctions. A Kozak sequence (A/GCCACCATGG) was engineered upstream
of the coding sequence to assure efficient translation initiation. The tissue plasminogen
activator secretion sequence (QMSPALTCLVLGLALVFGEGSA) was inserted between the
start codon and the start of the multi-epitope coding sequence to target the protein product to
the extracellular space and the MHC class II processing pathway. Two stop codons were
inserted following the multi-epitope coding sequence to assure translation termination. The
gene was synthesized by GeneArt (Toronto, Canada) and subsequently cloned into the pVAX1
plasmid DNA vaccine vector (Invitrogen Corporation, Carlsbad, CA).
2.4. Vaccination
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The HLA class II DNA construct was mixed with in vivo-JetPEI, a linear polyethylenimine
derivative, to enhance transfection according to the manufacturer’s instructions (Polyplustransfection Inc., New York, NY). To promote mucosal immunity, HLA-DRB1-transgenic
mice were inoculated intratracheally (i.t.) three times at 2-week intervals (i.e, on days 0, 14
and 28) with 25 µg DNA/50 µl saline according to the method of Kim and co-workers described
above [24]. On days 42 and 56, the mice were boosted i.t. with 25 µg/50 µl aliquots of the same
class-II-restricted peptides encoded by the construct. The peptides, synthesized commercially,
and phosphorothioate CpG ODN 1555 (Integrated DNA Technology; Coralville, IA) [26] were
co-packaged in sterically stabilized cationic liposomes as previously reported by other
investigators [27]. Briefly, small unilamellar liposomal vesicles were mixed with peptides and
CpG ODN, freeze-dried, and resuspended in distilled water to internalize peptides and CpG
ODN in liposomes. Non-vaccinated control mice were inoculated i.t. with unmodified pVAX1
vector and liposomes that contained CpG ODN only.
2.5. RNA extraction, purification, and quantitative real-time RT-PCR
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Total cellular RNA in representative lung, spleen and liver samples was extracted and purified
using TRIzol (Invitrogen Corporation, Carlsbad, CA). Real-time RT-PCR was conducted by
a slight modification of the methods we described previously [28]. Briefly, purified RNA was
reverse transcribed with QuantiTect reverse transcriptase (Qiagen Inc., Valencia, CA).
Quantitative gene expression analysis was performed using the Eppendorf Mastercycle ep
Realplex gradient S (Eppendorf, Westbury, NY) and SYBR green technology. iTaq SYBR
Green Supermix with ROX (BioRad Laboratories, Hercules, CA) was mixed with an equal
volume of RNase-free water containing 0.5 µM of both the forward and reverse primers, and
cDNA corresponding to 100 ng of total RNA input. Subsequently, 40 cycles were run each
consisting of 30 sec at 95°C followed by 1 min at 55°C and 30 sec at 72°C. At the end of the
run, melting curves were constructed by heating the samples to 95°C with a ramp time of 20
min to verify that single PCR products were generated. Ribosomal RNA (18S) was used as the
housekeeping standard. Copies of messenger and ribosomal RNAs were estimated from the
number of PCR cycles required for the fluorescent signal to reach a fixed intensity, the threshold
cycle (Ct). The mean number targeted gene mRNA copies/103 18S rRNA copies ± SE for
samples derived from six mice treated comparably is reported. The PCR primers listed in Table
2 (designed from published sequences using Primer3 software, Whitehead Institute,
Cambridge, MA) were purchased from Operon Biotechnologies, Inc. (Huntsville, AL).
2.6. Cytokine and chemokine analyses
The cytokines and chemokines present in representative tissue samples obtained from
individual mice were quantified using the Bio-Plex cytokine array system. The samples (50–
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100 µg/ml) were homogenized in calcium- and magnesium-free HBSS containing 0.5% Triton
X-100 and 2× complete protease inhibitor cocktail (Roche Diagnostics Corporation
Indianapolis, IN). Homogenates were incubated for 30 minutes on ice then centrifuged at
13,500g for 5 minutes at 4°C to remove cell debris. The supernatants were stored at −20°C
until assays are performed. Bio-Plex cytokine assay kits were purchased and used with the BioPlex 200 system in accordance with the manufacturer’s instructions (Bio-Rad Laboratories
GmbH, Munich, Germany). The following panel of potentially relevant cytokines and
chemokines were quantified: IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12 (p40), TNF-α, IFN-γ,
MIP-1α, MCP-1 and KC.
2.7. Statistical analysis
The data were analyzed using the SigmaStat statistics program (Jandel Scientific, San Rafael,
CA). Individual means were compared using a non-paired Student's t test or a Mann-Whitney
Rank Sum test. Data derived from 3 or more groups were compared by one-way analysis of
variance (ANOVA) followed by a Tukey test to identify the groups that differed significantly
(P <0.05).

3. Results
3.1. Epitope-based vaccination and LVS challenge
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HLA class II (DRB1*0401) transgenic mice were immunized i.t. with the DNA vaccine
construct shown in Figure 1, then boosted with the corresponding peptides formulated in
liposomes with CpG ODN 1555; control mice received unmodified pVAX1 vector and
liposomes that contained CpG ODN only. The mice were subsequently challenged i.t. with F.
tularensis LVS on day 18 following the final peptide boost. The data derived from 2 separate
experiments in which the mice were challenged with 2 LD50 (~2,560 CFUs; Figure 2A) or 5
LD50 (~6,400 CFUs; Figure 2B) are shown. Notably, while all the control mice challenged
with 5 LD50 died, ~60% of the vaccinated animals survived over the course of the 3-week
period following infection.
Relative to non-immunized controls, vaccinated mice challenged i.t. with F. tularensis LVS
exhibited a significant reduction in the bacterial burden of the lungs assessed on day 3 postinfection (Table 3). The numbers of organisms in the spleens and livers dissected from the
same animals were extremely low compared to the lungs; no detectable differences between
these organs obtained from vaccinated and control mice were determined.
3.2. Vaccination promotes rapid, proinflammatory cytokine production in the lungs of mice
challenged with F. tularensis LVS
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The expression of several proinflammatory cytokine mRNAs was up-regulated rapidly in the
lungs of vaccinated mice challenged i.t. with 6 LD50 F. tularensis LVS on day 18 postvaccination. Particularly, the expression of IL-12, TNF-α and IFN-γ messages was significantly
higher in the lungs of vaccinated animals at 4 hours post-infection i.t. while average IL-4
mRNA expression was lower, albeit variation between samples prohibited finding statistical
significance (Figure 3). By comparison, cytokine and chemokine mRNA expression was
generally lower in the lungs of vaccinated mice than non-vaccinated control mice at 3 days
post-infection correlating directly with the reduced number of organisms found at this time
(shown in Table 3). Notably, cytokine/chemokine mRNA expression was generally higher in
the lungs of both groups of mice on day 3 than at 4 hours post-infection.
Pro-inflammatory cytokine and chemokine protein levels were also generally higher in the
lungs of vaccinated, relative to control, mice at 4 hours post-infection i.t. with F. tularensis
LVS (Figure 4). While variations among individual cytokines/chemokines occurred, protein
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levels overall were higher in the lungs at 3 days than at 4 hours post-infection. However, in
contrast to 4 hours, no statistical difference was found in the levels of these proteins in the
lungs of the vaccinated versus non-vaccinated groups at 3 days. Notably, a strict correlation
between mRNA expression (illustrated in Figure 3) and protein production (Figure 4) was
lacking, which probably relates to the relative turnover rate of these two entities and the stability
of proteins.
3.3. Cytokine/chemokine levels in the spleens and livers of F. tularensis-infected mice
In contrast to the lungs in which there was no detectable difference on day 3 post-infection,
cytokine and chemokine protein levels were generally lower in the spleens of vaccinated mice
(Figure 5). In particular, the tissue concentrations of IL-6, IL-10, IL-12 and TNF-α were
significantly decreased in the spleens of vaccinated, relative to non-vaccinated, animals. The
cytokine/chemokine levels in the livers of control and vaccinated mice, on the other hand, were
comparable; only the concentration of IL-10 was diminished in the latter group.

4. Discussion
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Clinical studies conducted in the 1960s demonstrated the utility of F. tularensis LVS in
immunizing humans against exposure to a virulent pathogenic strain [13,29]. Despite its
development over 40 years ago, however, the basis for the attenuation of F. tularensis LVS,
protective antigens, and immunological mechanisms that underlie its efficacy remain
unresolved. These as well as other issues, e.g., variations in inherent pathogenicity, have
instigated a search for an improved, better defined tularemia vaccine. Given the effectiveness
achieved with F. tularensis LVS, strategies to develop a new generation vaccine have focused
largely upon attenuated organisms that possess only limited ability to survive, replicate, and
cause disease. Vaccination with a viable organism, however, continues to represent a potential
risk for normal, as well as immunocompromised individuals. In a mouse model, for example,
vaccination with a highly attenuated Type A strain of F. tularensis subspecies tularensis
administered i.n. caused severe tissue injury in the lungs even in the absence of extensive
bacterial replication [30]. Subunit vaccines offer an alternate approach with clear safety
advantages.
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The LPS-associated O-antigen is the only component of F. tularensis identified to date that,
by itself, is capable of stimulating protective immunity against systemic infections by virulent
Type B, or against respiratory challenge by either Type A or B strains [21,31]. Mice immunized
subcutaneously with LVS endotoxin-BSA conjugate were partially protected against aerosol
challenge with virulent type B, but were fully susceptible to aerosol challenge with virulent
type A strain [21]. A number of highly immunogenic proteins have been identified (e.g., FopA
and TUL4); none are able to elicit protective immunity [31,32].
The experiments reported herein document the efficacy of a F. tularensis subunit vaccine
composed of HLA class II-restricted epitopes, predicted by computer analyses of the microbial
genome and verified by the recognition of T cells obtained from individuals previously exposed
to tularemia [22]. Mouse MHC class II I-E molecules were not expressed by HLA DRB1
transgenic mice immunized in the experiments described herein, negating their potential role
in the results reported. This is notable inasmuch as promiscuous binding was a dominant
criterion employed in selecting the T cell epitopes incorporated into the vaccine construct used
[22]. Consequently, cross reactivity is expected and it is predicted that several epitopes would
bind to mouse MHC class II molecules if the molecules were expressed. Vaccinated HLA
DRB1 transgenic mice exhibited elevated resistance to a lethal dose of F. tularensis LVS
inoculated i.t. This finding is remarkable in several respects. First, the vaccine lacked MHC
class I-restricted epitopes required to elicit a CD8+ T cell response and maximum protection
against F. tularensis infection [22]. Moreover, 4 of the 14 epitopes incorporated into the vaccine
Vaccine. Author manuscript; available in PMC 2010 August 27.
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construct are expressed exclusively by the virulent, Schu4 strain of F. tularensis (i.e., not LVS
illustrated in Figure 1B) and, thus, presumably failed to elicit T cell responses relevant to
protective immunity in the challenge experiments reported here. It is pertinent to note that the
vaccine was only effective when administered i.t.; intramuscular vaccination with the DNA
vaccine construct alone failed to elicit protective immunity in mice against subsequent
challenge (data not shown). This result correlates with findings obtained by other investigators
who reported that vaccination by a mucosal route induced the greatest protection against
pneumonic tularemia [33].
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Relative to the controls, mice immunized with the epitope-based subunit vaccine described
herein exhibited increases in IL-12, TNF-α and IFN-γ mRNA expression, and IL-1β, IL-6,
IL-12, MIP-1α, MCP-1 and KC protein production in the lungs within a 4-hour period postinfection. IL-12, TNF-α and IFN-γ are critical factors in host resistance to F. tularensis
infections in mice [34]. While such cytokines initially derive from NK cells, macrophages and/
or dendritic cells during primary infection, they constitute an important component of the
adaptive immune response in which memory T lymphocytes serve as a primary cell source
during a secondary response to F. tularensis infection [33–35]. In this regard, immunized mice
challenged intradermally with a lethal dose of F. tularensis LVS exhibited the rapid, elevated,
local expression of IL-12, IFN-γ and TNF-α mRNAs correlating with a marked decrease in the
replication of bacteria at the site of infection [36]. In more recent studies, both CD4+ and
CD8+ T cells, and the production of IFN-γ were key factors in the vaccine-induced protection
of mice against respiratory challenge with the virulent type A strain of F. tularensis [33,37].
These findings correlate with those reported here in which increases in cytokine/chemokine
mRNA expression and/or protein production in vaccinated animals correlated with a
diminished number of organisms enumerated in the lungs at 3 days post-infection, and an
increased rate of survival.
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The elevated expression of both IL-12 and IFN-γ mRNA and production of IL-12 in the lungs
of vaccinated mice at 4 hours post-infection are particularly noteworthy. IL-12 is essential for
the induction of IFN-γ production by T lymphocytes, and a critical factor in host defenses to
respiratory F. tularensis LVS infections [38,39]. Mice deficient in either IL-12 or IFN-γ readily
succumbed to infections that were sublethal for wild-type animals [39]. Moreover, exogenous
IL-12 treatment prevented the death of mice infected with a lethal dose of F. tularensis LVS;
protection was dependent upon IFN-γ. The elevated protein concentration of IL-12, but not
IFN-γ, in the lungs of vaccinated mice at 4 hours post-infection supports the sequential
synthesis of these two cytokines and the requisite production of IL-12 for the induction of IFNγ synthesis in the lungs of mice infected i.n. with F. tularensis [39]. The rapid increase in IL-12
mRNA expression and protein production presumably by tissue macrophages in vaccinated,
relative to naïve, mice challenged with F. tularensis has been reported [36]. The mechanisms
that enable such an increase remain to be delineated.
TNF-α message expression was also elevated significantly in the lungs of vaccinated, relative
to control, mice at 4 hours post-infection i.t. with F. tularensis LVS. Like IL-12 and IFN-γ,
TNF-α is a key factor in host defenses to tularemia infections in mice [40]. Replication of the
organism is increased markedly in organs of TNF-deficient mice or mice treated with
neutralizing, anti-TNF monoclonal antibody [10,40]. As in the case of IFN-γ in the experiments
reported here, TNF-α message expression seemingly preceded TNF-α production so that
protein levels in the lungs of vaccinated and control mice were equivalent at 4 hours postinfection despite detecting elevated mRNA levels in the vaccinated group at this time.
While it is widely believed that alveolar macrophages constitute the principal target of F.
tularensis infections of the lungs, they also represent a dominant cell population in host
defenses [41]. In this regard, it has been suggested that the lack of alveolar macrophage
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activation and the production of cytokines contributes to the increased susceptibility of TLR2deficient mice to pneumonic tularemia [42]. The elevated production of cytokines and
chemokines normally associated with macrophages (i.e., IL-1β, IL-6, IL-12, MIP-1α, MCP-1
and KC) in the lungs of vaccinated mice within a 4-hour period following infection supports
this purported role of alveolar macrophages in cytokine/chemokine production and host
defenses to F. tularensis. As noted in the Results Section, the absence of a strict correlation
between message expression (Figure 3) and protein production (Figure 4) conceivably derives
from a difference in stability of the mRNA transcript and protein product [43]. As in the case
of IL-12 discussed above, the factors that trigger a rapid increase in mRNA expression and/or
the production of these cytokines/chemokines in the lungs of vaccinated mice challenged i.t.
with F. tularensis are unclear.
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Although cytokine and chemokine protein levels were frequently higher in the lungs of
vaccinated animals at 4 hours post-infection, these same proteins were generally lower (albeit
not significantly) in the lungs at 3 days (Figure 4). Similarly, these same cytokines and
chemokines were lower in the spleens of vaccinated mice on day 3 post-infection (Figure 5).
Other investigators report similar findings, that is, decreases in pro-inflammatory cytokine
(TNF-α, IFN-γ, IL-6 and/or MCP-1) concentrations in tissues derived from vaccinated (relative
to control) mice after an extended period following challenge i.n. with F. tularensis [16,20].
Indeed, the exaggerated production of pro-inflammatory cytokines such as MCP-1 and IL-6
in the tissues of mice infected i.n. with F. tularensis was found to correlate directly with critical
illness, sepsis and organ failure [44].
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In conclusion, the experiments reported here demonstrate the efficacy of a subunit vaccine
constructed of multiple epitopes recognized by T cells derived from individuals previously
exposed to tularemia and capable of eliciting protective immunity in “humanized” HLA class
II (DRB1*0401) transgenic mice. Vaccinated mice challenged intratracheally with a lethal
dose of F. tularensis LVS exhibited a rapid increase in pro-inflammatory cytokine production,
a diminished number of organisms in the lungs, and an increased rate of survival. At later time
points during the course of infection, proinflammatory cytokine/chemokine levels in the tissues
of vaccinated animals are reduced for the most part correlating with the reduction in bacterial
burden and critical illness. These results suggest that an epitope-based approach might be
widely applicable to the development of vaccines against other intracellular bacterial
pathogens. Experiments involving HLA-A2.1-/HLA-DRB1-double transgenic mice
vaccinated with DNA constructs (and the corollary peptides) that encode both HLA class Iand class II-restricted F. tularensis-specific epitopes, and subsequent challenge i.t. with the
virulent, Schu4 strain of F. tularensis are envisioned. Relative to the attenuated vaccines
currently being developed, an epitope-based vaccine with demonstrated efficacy against
aerosolized F. tularensis subtype tularensis would be safer, more readily approved by
governing agencies, and easier to market.
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Figure 1. Multi-epitope DNA vaccine construct
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A synthetic gene encoding a concatamer of 14 validated tularemia T cell epitopes was inserted
into the pVAX1 DNA vaccine vector (A). Expression of the concatamer was directed for
secretion by the tissue plasminogen activator (TPA) N-terminal signal sequence. The synthetic
gene was constructed of 6 sequences that were 100% conserved between F. tularensis LVS
and the virulent Schu4 strain, 4 that were partially conserved, and 4 that were only found in
F. tularensis Schu4 (B).
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Figure 2. Epitope-based vaccine induces protective immunity to tularemia in HLA class II
transgenic mice

Groups of vaccinated and control mice were challenged i.t. with 2 LD50 (A) or 5 LD50 (B) F.
tularensis LVS and survival was monitored over a 3-week period. Three experiments
conducted under similar conditions yielded comparable results; the data derived from 2 of these
experiments are shown.
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Figure 3. Cytokine/chemokine mRNA expression in the lungs of vaccinated mice is rapidly upregulated following i.t. challenge with F. tularensis LVS

Groups of control (solid bar) and vaccinated (open bar) mice were infected i.t. with 6 LD50 F.
tularensis LVS. The lungs were dissected at 4 hours and 3 days post-infection; cytokine and
chemokine mRNA expression was quantified by real-time RT-PCR. Data are the means ± SD
derived from 4 mice treated comparably. A second experiment yielded similar results.
*Vaccinated group is significantly different from control: P<0.05.
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Figure 4. Proinflammatory cytokine and chemokine protein production is up-regulated in the lungs
of vaccinated mice shortly following i.t. inoculation of F. tularensis LVS

Groups of control and vaccinated mice were challenged i.t. with 6 LD50 F. tularensis LVS. At
4 hours (top panel) and 3 days (bottom panel) post-infection, the lungs were dissected, and the
cytokines and chemokines listed were quantified by Bio-Plex cytokine bead array analysis.
Data are the means ± SD derived from 4 mice treated comparably in each group. A second
experiment yielded similar results. *Vaccinated group is significantly greater than control:
P<0.05. Notably, IL-4 concentrations (not shown) were below the level of detection.
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Figure 5.

Proinflammatory cytokine/chemokine protein production is down-regulated in the spleens of
vaccinated mice challenged i.t. with F. tularensis LVS. Groups of control and vaccinated mice
were challenged i.t. with 6 LD50 F. tularensis LVS. At 3 days post-infection, the spleens (top
panel) and livers (bottom panel) were dissected from each group, and the cytokines and
chemokines listed were quantified by Bio-Plex cytokine bead array analysis. Data are the means
± SD derived from 4 mice treated comparably. A second experiment yielded similar results.
*Vaccinated group is significantly less than control: P<0.05. IL-4 concentrations were too low
to be detected (not shown).
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Table 1

Epitopes selected for vaccine construct
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Peptide ID

AA Sequence

Protein
Location

GenBank
Accession

FOPA 102 (AKA
Fopa-2)

IGYNINKYFAVQYNQLVGRVFAGLGE

102–127

GI-1332665

FOPA 176 (AKA
Fopa-4)

SVDYRYIQTMAPSNISGA

176–193

GI-1332665

GS1_Secr_II_3001

SLGYELWRRYNGFPINLN

273–290

GI-56707198

GS1_hemK_II_3003

PLAYILGYKYFWNQKLYVTKD

51–71

GI-56707339

GS1_Chitn_II_3004

ADGKKYYLAIAVNGARSRIEAM

292–313

GI-56707834

GS1_Epim_II_3005

KEKYYKINTQLTYDLAKQ

46–63

GI-56708503

GS1_Hyp_II_3007

NIIMVKVFVYNLNNNINAIK

24–43

GI-56707430

GS1_FAD_II_3015

GEQFAFRPNNKITIAMV

314–330

GI-56708305

GS1_Hyp_II_3017

ENGIWKVNRPNPGPVTIA

127–144

GI-56708544

GS2_pilNBP_II_3018

AESLQIVISQRLLKRKGGGRVAAYEV

258–283

GI56707266

GS2_1699_II_3019

HKDFNFLLSPNQPILLDIQ

247–265

GI56708708

GS2_1715c_II_3023

RGDVKSFIPLYLRISGKASSALF

185–207

GI56708724

GS2_1715c_II_3024

FSDMEIRVRFGLYSKQSASKL

419–439

GI56708724

GS2_1715c_II_3025

DRLVRGFYFLLRRMVKNRNTKVGSHN

899–924

GI56708724

Protein
Description
immunogenic
chaperone
protein
immunogenic
chaperone
protein
Secretion
protein
hemK protein
homolog
chitinase
family 18
protein
UDP-glucose
4-epimerase
hypothetical
membrane
protein
FAD binding
family protein
hypothetical
protein
FTT1506
Type IV pili
nucleotidebinding protein
hypothetical
protein
FTT1699
hypothetical
protein
FTT1715c
hypothetical
protein
FTT1715c
hypothetical
protein
FTT1715c

Column 1: peptide ID, composed of Genome Scan 1 (GS1; putative secreted protein) or GS2 (confirmed expressed protein), abbreviated description of
the parent protein, MHC class predicted to bind the peptide, a four-digit ID number; Column 2: amino acid sequence; Column 3: GenBank assession of
parent protein; and Column 4: protein description [22].
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Table 2

Real-time RT-PCR Primers
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Gene

GenBank
accession

Orientation

Interleukin-1β

NM_008361

Interleukin-2

NM_008366

Interleukin-4

NM_021283

Interleukin-6

NM_031168

Interleukin-10

NM_010548

Interleukin-12 (p40)

NM_008352

IFN-γ

NM_008337

TNF-α

NM_013693

MIP-1α (Ccl3)

NM_011337

MCP-1 (Ccl2)

NM_011333

KC (Cxcl1)

NM_008176

18S ribosomal
RNA

XR_000144

forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse

Primer
sequence
TCACAGCAGCACATCAACAA
TGTCCTCATCCTGGAAGGT
CCCACTTCAAGCTCCACTTC
ATCCTGGGGAGTTTCAGGTT
CCTCACAGCAACGAAGAACA
ATCGAAAAGCCCGAAAGAGT
AGTTGCCTTCTTGGGACTGA
CAGGTCTGTTGGGAGTGG
CCAAGCCTTATCGGAAATGA
TTCACAGGGGAGAAATCG
GGAAGCACGGCAGCAGAATA
AACTTGAGGGAGAAGTAGGAATG
ACTGGCAAAAGGATGGTGAC
ACCTGTGGGTTGTTGACCTC
GTTCTGCAAAGGGAGAGTGG
GCACCTCAGGGAAGAGTCT
ACCATGACACTCTGCAACCA
CCCAGGTCTCTTTGGAGTCA
CCCACTCACCTGCTGCTACT
TCTGGACCCATTCCTTCTTG
GCTGGGATTCACCTCAAGAA
TGGGGACACCTTTTAGCATC
AATGGTGCTACCGGTCATTCC
ACCTCTCTTACCCGCTCTC
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Amplicon
size
112
155
155
103
162
180
211
106
202
164
169
192
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Table 3

The bacterial burden of the lungs is decreased in vaccinated micea
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Tissue

CFUs/mg tissue

Lungs
Liver
Spleen

pVAX1 control

Vaccine construct

27,352 ± 10,251
53 ± 16
13 ± 5

13,561 ± 1,428b
66 ± 55
17 ± 9

a

Groups (n=4) of control and vaccinated mice were challenged i.t. with 2 LD50 F. tularensis LVS. Values are the mean colony forming units ± SD/mg

tissue dissected on day 3 postinfection.
b

Significantly less than pVAX1 control; P=0.029 (Mann-Whitney Rank Sum Test).
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